Canton Fitzgerald's Elemer Piros initiated Dimension Therapeutics Inc (NASDAQ: DMTX) at Buy with a $32.00 price objective.
"Dimension has assembled a suite of potentially best-in-class liver-targeted gene therapies" with a $275-million-dollar licensing agreement with Bayer Healthcare, said Piros. The analyst was impressed with Dimension's intellectual property and "world-class pharma and biotech executives" which would allow Dimension to "accomplish an ambitious set of development goals."
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Additionally, Piros noted that Ornithine transcarbamylase (OTC) deficiency, an issue which Dimension wishes to solve, is currently being treated with a drug that costs ~$250,000 a year taken for a lifetime."
Shares of Dimension Therapeutics last closed at $8.45.